Saudi Arabia-based healthcare company Baraya Extended Care has inaugurated its first rehabilitation outpatient clinic in Riyadh.
The facility will offer a range of therapies, including physical, occupational and speech and language therapy, alongside advanced and intensive rehabilitation services.
It can deliver up to 3,000 rehabilitation sessions each month.
Saudi Arabia is currently facing a critical shortage of long-term post-acute care (LTPAC) and rehabilitation beds, with this area highlighted as a healthcare priority under Saudi Arabia's Vision 2030 strategy.
Public hospitals in the company are currently facing capacity issues, which the expansion of specialised facilities such as Baraya's new clinic aims to address.
serve as a more effective solution to reduce the strain on existing hospital resources.
Baraya is committed to providing holistic long-term care, rehabilitation and at-home healthcare services in Saudi Arabia by using new therapeutic tools, technologies and treatment methods.
The company is scheduled to open its second outpatient clinic in Jeddah next month.
In addition, Baraya's first in-patient long-term care hospital is under development and anticipated to launch in Abha by the end of next year.
The facility will have 216 beds and aim to address chronic and complex conditions among the ageing Saudi population, as well as treat younger individuals who have suffered catastrophic injuries or have congenital diseases.
Baraya Extended Care chief executive Jad Halaby said: “We are committed to addressing the critical need for extended care services in Saudi Arabia.
“Through our initial nine facilities across Riyadh, Jeddah and Abha, we will leverage TVM Capital Healthcare’s expertise to deliver cutting-edge solutions aligned with Vision 2030’s healthcare goals, improving the lives of patients and families in Saudi Arabia by providing exceptional extended care services.”
Earlier this year, TVM made a substantial equity investment in Vietnam-based eye care provider Alina Vision alongside The Fred Hollows Foundation and Rohto Pharmaceutical.
